Search

Now showing items 1-4 of 4

Pharmacokinetics of isoniazid, rifampin,and pyrazinamide in children younger than two years of age with tuberculosis: Evidence for implementation of revised World Health Organization recommendations

Thee S.; Seddon J.A.; Donald P.R.; Seifart H.I.; Werely C.J.; Hesseling A.C.; Rosenkranz B.; Roll S.; Magdorf K.; Schaaf H.S. (2011)

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

Schaaf H.S.; Parkin D.P.; Seifart H.I.; Werely C.J.; Hesseling P.B.; Van Helden P.D.; Maritz J.S.; Donald P.R. (2005)

Aims: To define the pharmacokinetics of isoniazid (INH) in children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype. Methods: The first order elimination rate constant (k) and area under the ...

The association of age and elimination of isoniazid: An example of median regression with heteroscedasticity

Maritz J.S.; Donald P.R.; Schaaf H.S.; Seifart H.I.; Parkin D.P.; Werele C. (2003)

The rate of elimination of the tuberculosis drug INH(k) varies from person to person, is characteristic of certain genotypes and has been thought to be age dependent. The data in this paper are subjected to a regression ...

Pharmacokinetics of ethionamide in children

Thee S.; Seifart H.I.; Rosenkranz B.; Hesseling A.C.; Magdorf K.; Donald P.R.; Schaaf H.S. (2011)

Ethionamide (ETH), a second-line antituberculosis drug, is frequently used in treating childhood tuberculosis. Data supporting ETH dose recommendations in children are limited. The aim of this study was to determine the ...